- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02470689
Diacerin for the Treatment of Epidermolysis Bullosa Simplex
Epidermolysis bullosa simplex type Dowling-Meara (EBS-DM) is one of the most severe subtypes of EBS. Blisters and erosions of the skin and mucous membranes upon minor trauma are the consequence of dominantly inherited mutations in either the keratin 5 (K5) or keratin 14 (K14) gene, which encode proteins constituting the intermediate filament (IF) network in basal keratinocytes . Autosomal dominant mutations lead to a conformational change and an increased self-aggregation of the protein. Upon stress, aggregates present in the periphery of the cytoplasm, subsequently leading to the disintegration and collapse of the IF network. Clinically, patients suffer from blistering of the skin and mucous membranes upon minor trauma, resulting in an impaired life quality due to pain and pruritus . In vitro studies on Dowling-Meara keratinocytes revealed a significant upregulation of the pro-inflammatory cytokine interleukin-1beta (IL-1ß). Apart from paracrine effects of IL-1ß upon wounding (e.g. attraction of lymphocytes, activation of dermal fibroblasts), IL-1ß also activates keratinocytes via the cjun N-terminal kinase (JNK) stress pathway. The activation of this pathway leads to the activation of a number of transcription factors and the enhanced transcription of a number of genes, like matrix metalloproteinases, kallikreins, but also IL-1ß itself and K14 . Interestingly, this state of activation is constitutive and was also found in keratinocytes from non-lesional sites. It seems that the upregulation of IL-1ß and K14 in the presence of dominant Dowling-Meara mutations, results in a positive feedback loop, potentially aggravating the EBS-DM phenotype. This was strongly corroborated by the fact that when impairing IL1ß signaling, using IL-1ß neutralizing antibody (IL-1Ab) or the small molecule diacerein, expression levels of IL-1ß and K14 decreased and keratinocytes were much less susceptible to heat shock in vitro . Furthermore, activation levels of JNK widely correlated with expression levels of K14 and IL-1ß. (Wally V et al, 2013). These findings led to the hypothesis that blocking IL-1ß will also lead to an amelioration of the EBSDM phenotype in effected patients. Based on previous in vitro findings diacerein was chosen to be topically applied in a pilot study with five patients suffering from EBS-DM. In that study , each participant received 1% diacerein-cream for one armpit, and placebo for the other (randomized withdrawal). The number of blisters was reduced significantly (left: -78%; right: -66% of baseline) within two weeks and remained significantly below the initial level even during withdrawal in four patients. These findings pointed to a relevant effect of diacerein and provide important information for our confirmative study.
Diacerein is a component of the rhubarb root, which is reported to block the release of active IL-1b by inhibiting plasma membrane-bound IL-1 converting enzyme . Diacerien is already approved for systemic application in osteoarthritis . In general, small molecules (SM) are low molecular weight compounds with biological functions that can influence molecular processes. They allow a symptomatic treatment, offering a short-term benefit for patients in terms of an amelioration of the phenotype. Although this kind of treatment does not correct genetic alterations, it can still be highly beneficial by damping down disease symptoms, thereby increasing life quality and minimizing secondary manifestations.
It is important to emphasize that besides dressings, there are currently no other treatments, therefore, investigators do not prevent an accepted treatment for the patient and there is no risk for the participant. The treatment will be given only to the armpits although the disease can involve other areas, so stopping dressings in the armpits during the study does not risk the patient. Should there be any deterioration of the patient, whether it is related to the treatment with diacerein or not, investigators will stop the use of diacerein.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Dvora Cohen, M.A
- Phone Number: 972-3-6973768
- Email: dvorac@tlvmc.gov.il
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of EBS-DM
- An age between 6 - 19
Exclusion Criteria:
- Lack of mutation analysis
- Intolerance to a component of the cream
- Pregnancy or Lactation
- Contemporaneous participation in another clinical trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: TRIPLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Diacerin cream 1%
|
Diacerin tablet solubule in ultraphil cream
|
Placebo Comparator: ultraphil cream
|
Diacerin tablet solubule in ultraphil cream
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of blisters
Time Frame: 4 weeks
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of blisters
Time Frame: 3 months period
|
3 months period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eli Sprecher, Prof., Head of Dermatology Department, Ichilov medical center
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TASMC-15-SE-135-14-CTIL
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Epidermolysis Bullosa Simplex
-
Castle Creek Pharmaceuticals, LLCCompletedDystrophic Epidermolysis Bullosa | Epidermolysis Bullosa Simplex | Junctional Epidermolysis Bullosa | Epidermolysis Bullosa (EB)United States
-
TWi Biotechnology, Inc.RecruitingGeneralized Epidermolysis Bullosa SimplexUnited States, Taiwan, Australia, Philippines
-
Centre Hospitalier Universitaire de NiceCompletedEpidermolysis Bullosa Simplex Dowling MearaFrance
-
Joyce TengRecruitingHealthy | Epidermolysis Bullosa | Genetic Skin Disease | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, JunctionalUnited States
-
ProgenaBiomeRecruitingEpidermolysis Bullosa | Epidermolysis Bullosa Dystrophica | Epidermolysis Bullosa SimplexUnited States
-
InMed Pharmaceuticals Inc.CompletedEpidermolysis Bullosa Dystrophica | Epidermolysis Bullosa Simplex | Epidermolysis Bullosa, Junctional | Kindler SyndromeFrance, Germany, Greece, Israel, Italy
-
Castle Creek Pharmaceuticals, LLCTerminatedEpidermolysis Bullosa SimplexUnited States, Israel, Australia, Austria, France, Germany, Netherlands, United Kingdom
-
Castle Creek Pharmaceuticals, LLCCompletedEpidermolysis Bullosa | Epidermolysis Bullosa SimplexUnited States
-
Centre Hospitalier Universitaire de NiceUnknownEpidermolysis BullosaFrance
-
University Hospital, ToulouseRecruitingEpidermolysis Bullosa SimplexFrance
Clinical Trials on Diacerin cream
-
University of North Carolina, CharlotteTeva Branded Pharmaceutical Products R&D, Inc.CompletedMultiple SclerosisUnited States
-
Incyte CorporationCompletedCutaneous Lichen PlanusUnited States, Canada
-
Incyte CorporationRecruitingPrurigoUnited States, Spain, France, Poland, Germany, Belgium, Netherlands, Argentina, Italy, Canada, Chile, Brazil
-
Edesa Biotech Inc.JSS Medical Research Inc.Active, not recruitingAllergic Contact DermatitisUnited States, Canada
-
LEO PharmaCompletedChronic Hand EczemaUnited States, Germany, Denmark
-
LEO PharmaCompletedHealthy VolunteersGermany
-
LEO PharmaTerminatedDiscoid Lupus ErythematosusUnited States, France, Germany, Denmark
-
Incyte CorporationRecruitingPrurigo NodularisSpain, Korea, Republic of, United States, Poland, Italy, Austria, Germany, Canada, Switzerland, Australia, France, Denmark, Bulgaria
-
LEO PharmaCompletedHealthy VolunteersGermany
-
GlaxoSmithKlineCompletedDermatitis, AtopicUnited States, Canada, Japan